Renaissance Capital logo

Context Therapeutics Scheduled, Nasdaq: CNTX

Phase 2 biotech developing therapeutics for female cancers.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, our founders and management team have decades of experience identifying and characterizing the mechanisms that drive cancer initiation and subsequent relapse in women with cancer and have been associated with the development of products such as Kisqali (ribociclib), Arimidex (anastrozole) and Afinitor (everolimus) to treat such cancers. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer. Our first program and lead product candidate, onapristone extended release (“ONA-XR”), is a selective and potentially potent antagonist of the progesterone receptor (“PR”), a receptor that is activated by the hormone progesterone and that has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, that are prescribed to treat female hormone-dependent cancers. In 2019, we initiated our Phase 2 trial of ONA-XR in women with ovarian cancer who express high levels of progesterone receptor (“PR+”) and we expect to report preliminary data from this trial in the second half of 2021.
more less
IPO News for Context Therapeutics
more
IPO Data
IPO File Date 05/27/2021
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 1.5
Deal Size ($mm) $20
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 1.5
Deal Size ($mm) $20
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Philadelphia, PA
Founded 2015
Employees 2
Website www.contexttherapeutics.com